Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 6/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 2/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 1/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.70 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.68 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.68 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.68 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Stanolone SCHEMBL14154693 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL11654234 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL15163 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL24684703 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL13172965 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL24410503 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL15963443 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL5534749 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL21442439 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR | |
| Stanolone SCHEMBL12991785 | 1.00 | SHBG (1.00) | SHBGGPBAR1CYP19A1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202413-B2 | Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| CN-107873030-A | 5‑HT2CReceptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2018-04-03 | — | — | CN | disclosed |
| US-20160251391-A9 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| US-20150361125-A1 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | UNIV WASHINGTON (US) | 2015-12-17 | — | — | US | disclosed |
| US-9114163-B2 | Medication against breast cancer and related diseases | MABEL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| EP-2018170-B1 | Medication against breast cancer | MABEL GMBH (DE) | 2012-07-25 | — | — | EP | disclosed |
| WO-2008100161-A9 | SURFACE PLASMON RESONANCE ASSAY FOR STEROIDS | THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED (NZ) | 2009-09-11 | — | — | WO | disclosed |
| US-20090111784-A1 | MEDICATION AGAINST BREAST CANCER AND RELATED DISEASES | CURADIS GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090104122-A1 | DETECTION OF MEMBRANE ANDROGEN RECEPTOR (mAR) AGENTS | MEDEXIS S.A. (GR) | 2009-04-23 | — | — | US | disclosed |
| EP-2018170-A2 | MEDICATION AGAINST BREAST CANCER AND RELATED DISEASES | Teichmann, Alexander Tobias (DE) | 2009-01-28 | — | — | EP | disclosed |
| EP-2008099-A2 | DETECTION OF MEMBRANE ANDROGEN RECEPTOR (MAR) AGENTS | Medexis S.A. (GR) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008100161-A1 | SURFACE PLASMON RESONANCE ASSAY FOR STEROIDS | THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED (NZ) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007131737-A2 | MEDICATION AGAINST BREAST CANCER AND RELATED DISEASES | TEICHMANN ALEXANDER TOBIAS (DE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007123682-A2 | DETECTION OF MEMBRANE ANDROGEN RECEPTOR (MAR) AGENTS | MEDEXIS S.A. (GR) | 2007-11-01 | — | — | WO | disclosed |
| WO-2000066613-A1 | BONE TARGETING AGENTS FOR OSTEOPOROSIS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| US-4181669-A | A CARBODIIMIDE WITH ACID CATALYSTS AS A CONDENSATION AGENT | AKTIEBOLAGET LEO (SE) | 1980-01-01 | — | — | US | disclosed |
| US-4180504-A | Method for the preparation of esters | AKTIEBOLAGET LEO (SE) | 1979-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111784-A1 | MEDICATION AGAINST BREAST CANCER AND RELATED DISEASES | CYP19A1, SHBG, ESRRB | SHBG 2/4885GPBAR1 32/4885CYP19A1 1/4885 |
| US-20150361125-A1 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA5, GABRA3 | SHBG 190/4885GPBAR1 117/4885CYP19A1 300/4885 |
| US-10202413-B2 | Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for GABA type-A receptors | GABRA4, GABRA5, GABRA3 | SHBG 190/4885GPBAR1 117/4885CYP19A1 300/4885 |
| US-20160251391-A9 | NEUROACTIVE ENANTIOMERIC 15-, 16- AND 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRA4, GABRA5, GABRA3 | SHBG 190/4885GPBAR1 117/4885CYP19A1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.